Pepinemab is under clinical development by Vaccinex and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase II drugs for Pancreatic Ductal Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Pepinemab LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pepinemab overview
Pepinemab (VX-15) is under development for the treatment of multiple sclerosis (MS), metastatic adenocarcinoma of the pancreas, pancreatic ductal adenocarcinoma, metastatic melanoma, recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), non-small cell lung cancer, Alzheimer's disease, osteosarcoma, squamous cell carcinoma of the head and neck, oropharyngeal cancer, oral cavity cancer, laryngeal cancer, rett syndrome, relapsed/refractory solid tumors such as metastatic colorectal, HER2-positive (HER2+) metastatic breast cancer, papillary thyroid cancer, pancreatic ductal adenocarcinoma and pediatric patients with solid tumors. It is administered intravenously. The drug candidate is a monoclonal antibody targeting semaphorin 4D (SEMA4D). The drug candidate is developed based on proprietary ActivMab technology, which involves a vaccinia virus-based vector to express antibodies in mammalian cells. It was also under development for the treatment of melanoma.
It was under development for the treatment of Huntington's disease.
Vaccinex overview
Vaccinex is a clinical-stage biotechnology company. It discovers and develops targeted biotherapeutics to treat neurodegenerative diseases, cancer and autoimmune disorders. The company’s lead platform technologies include antibody platform and ActivMAb, SEMA4D and antibody discovery platform. Vaccinex through its antibody platform develops its lead product candidate VX15, for the treatment of various indications such as neurodegenerative diseases, neuroinflammatory and cancer. The company also develops VX5 that is in preclinical development for the treatment of autoimmune disorders. It has partnership with biotechnology and biopharmaceutical companies to enhance its product candidates. Vaccinex is headquartered in Rochester, New York, the US.
For a complete picture of Pepinemab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
